drugset / Trial / NCT01634061
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label study of abiraterone acetate in combination with BEZ235 and abiraterone acetate in combination with BKM120 in CRPC patients with abiraterone acetate failure.
Timeline
- Start
- 2012-09
- Primary completion
- 2015-07
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buparlisib | Small molecule | 60 mg | Oral |
| Subject | Buparlisib | Small molecule | 80 mg | Oral |
| Subject | Buparlisib | Small molecule | 100 mg | Oral |
| Subject | Dactolisib | Small molecule | 200 mg | Oral |
| Subject | Dactolisib | Small molecule | 300 mg | Oral |
| Subject | Dactolisib | Small molecule | 400 mg | Oral |